Stuart Lutzker, M.D., Ph.D., is a distinguished figure in the field of oncology and drug development, currently serving as President of Research and Development at ARRIVENT BIOPHARMA INC. Dr. Lutzker's academic journey is marked by his dual degrees in medicine and philosophy, which have provided him with a robust foundation in both clinical practice and scientific research. His career trajectory showcases a deep commitment to advancing cancer treatments, with significant stints at leading pharmaceutical companies such as Merck, where he held various senior roles in oncology drug development. Throughout his career, Dr. Lutzker has been instrumental in the development and approval of several groundbreaking cancer therapies. His expertise spans multiple therapeutic modalities, including small molecules, biologics, and immuno-oncology agents. Notable achievements include his contributions to the development of KEYTRUDA® (pembrolizumab), a revolutionary immunotherapy that has transformed the treatment landscape for numerous cancer types. His strategic vision and scientific acumen have earned him recognition as a thought leader in the oncology community. At ARRIVENT BIOPHARMA INC, Dr. Lutzker plays a pivotal role in steering the company's research and development efforts. His leadership is focused on identifying and advancing novel cancer therapies that address unmet medical needs. Under his guidance, ARRIVENT is working to build a robust pipeline of innovative treatments, leveraging cutting-edge science and strategic collaborations. Dr. Lutzker's commitment to translating scientific discoveries into meaningful patient outcomes continues to drive the company's mission to make a significant impact in the fight against cancer.